💥 Gate Square Event: #PostToWinTRUST 💥
Post original content on Gate Square related to TRUST or the CandyDrop campaign for a chance to share 13,333 TRUST in rewards!
📅 Event Period: Nov 6, 2025 – Nov 16, 2025, 16:00 (UTC)
📌 Related Campaign:
CandyDrop 👉 https://www.gate.com/announcements/article/47990
📌 How to Participate:
1️⃣ Post original content related to TRUST or the CandyDrop event.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinTRUST
4️⃣ Include a screenshot showing your CandyDrop participation.
🏆 Rewards (Total: 13,333 TRUST)
🥇 1st Prize (1 winner): 3,833
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world’s largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.